N@N

Adaltis Inc.: Adaltis Announces New Executive Vice President and Chief Financial Officer

^{Published on 2009-03-23 08:31:37, Last Modified on 2009-03-23 08:32:12 - Market Wire}
 

MONTREAL, QUEBEC--(Marketwire - March 23, 2009) - Adaltis Inc. (TSX:ADS), an international in vitro diagnostic company, today announced that its Board of Directors has appointed Mr. David Gardner as Executive Vice President and Chief Financial Officer of Adaltis Inc., effective March 20, 2009.

"As we head into an accelerated period of growth with the launch of Eclectica^TM and the growing prospects opening up for us in China, the appointment of David Gardner as the new Executive Vice President and CFO of Adaltis Inc. comes at a very exciting time in our history", said Peter Bambic, President and Chief Executive Officer. "David brings a wide breadth of financial experience from public companies operating in the international environment including recently as Corporate Controller of Adaltis. This background will certainly benefit us as we enter this crucial new phase in our history", added Mr. Bambic.

About David Gardner

Mr. Gardner graduated from Concordia University and is a Certified General Accountant. With over 20 years of Finance experience, he has held various positions of increasing responsibility in Finance both in Chief Financial Officer and Controllership roles. Mr. Gardner has previously been employed in senior roles at Bell Canada and Fujitsu Consulting.

About Adaltis

Adaltis is an international in vitro diagnostic company with a mission to become a leading provider of in vitro diagnostic products in emerging markets, with a particular focus on China.

With the strategic advantage of its "state of the art" reagent manufacturing facility located in Shanghai, China, a complete IVD product offering targeting emerging markets, and a strong international sales and distribution platform, Adaltis is able to manufacture high-quality products in a low-cost GMP environment, in order to service existing markets in Europe, while providing a platform to penetrate the high-growth Chinese in vitro diagnostic market.

Adaltis is headquartered in Montreal, with offices in China, India, Italy and Mexico.